City Holding Co. lowered its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.0% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,124 shares of the company’s stock after selling 321 shares during the quarter. Johnson & Johnson makes up approximately 0.9% of City Holding Co.’s holdings, making the stock its 28th biggest holding. City Holding Co.’s holdings in Johnson & Johnson were worth $4,979,000 at the end of the most recent reporting period.
A number of other hedge funds have also made changes to their positions in JNJ. Moneta Group Investment Advisors LLC grew its holdings in Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after acquiring an additional 54,326,454 shares during the last quarter. Norges Bank bought a new stake in Johnson & Johnson during the 4th quarter worth about $4,609,399,000. Morgan Stanley grew its holdings in Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after acquiring an additional 4,521,062 shares during the last quarter. Nordwand Advisors LLC bought a new stake in Johnson & Johnson during the 4th quarter worth about $785,273,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in Johnson & Johnson by 15.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after acquiring an additional 3,849,148 shares during the last quarter. Institutional investors and hedge funds own 67.57% of the company’s stock.
Analysts Set New Price Targets
A number of equities research analysts have commented on JNJ shares. Raymond James decreased their price objective on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a report on Wednesday, April 19th. TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, May 19th. Credit Suisse Group increased their price target on shares of Johnson & Johnson from $168.00 to $170.00 in a research report on Friday, May 5th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Thursday, May 18th. They issued a “strong-buy” rating on the stock. Finally, Atlantic Securities cut their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 19th. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $171.57.
Insider Activity
Johnson & Johnson Stock Performance
Shares of JNJ stock opened at $165.52 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The company has a market capitalization of $430.14 billion, a P/E ratio of 34.63, a price-to-earnings-growth ratio of 2.80 and a beta of 0.54. The company’s 50 day moving average price is $160.79 and its two-hundred day moving average price is $163.04. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $181.04.
Johnson & Johnson (NYSE:JNJ – Free Report) last posted its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The company had revenue of $24.75 billion for the quarter, compared to the consensus estimate of $23.61 billion. During the same period last year, the company earned $2.67 earnings per share. The firm’s revenue was up 5.6% compared to the same quarter last year. On average, analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd were issued a $1.19 dividend. The ex-dividend date of this dividend was Monday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.88%. Johnson & Johnson’s dividend payout ratio (DPR) is 99.58%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- MarketBeat Week in Review – 6/26 – 6/30
- Tesla: Can Downgrades Make Sense After A 170% Rally?
- Buffett’s Berkshire Increases Stake In Occidental Petroleum (OXY)
- Rally Gains Momentum On Soft PCE Data
- Bank of America, JPMorgan, Goldman Sachs Set For Dividend Growth?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
